Polyrizon (PLRZ) files Form 6-K on intranasal naloxone hydrogel data

Rhea-AI Filing Summary

Polyrizon Ltd. submitted a Form 6-K for December 2025, mainly to furnish a press release dated December 11, 2025. The press release is titled “Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program,” highlighting progress in this intranasal treatment initiative.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of December 2025

Commission file number: 001-42375

Polyrizon Ltd.

(Translation of registrant’s name into English)

5 Ha-Tidhar Street

Raanana, 4366507, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on December 11, 2025, titled “Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program.”

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Polyrizon Ltd.
Date: December 11, 2025	By:	/s/ Tomer Izraeli
	Name:	Tomer Izraeli
	Title:	Chief Executive Officer

3

FAQ

What does Polyrizon Ltd. (PLRZ) report in this Form 6-K?

Polyrizon Ltd. reports a Form 6-K for December 2025 to furnish a press release dated December 11, 2025. The filing itself contains no financial data, focusing instead on attaching this corporate update as an exhibit for investors.

What is the subject of Polyrizon Ltd.’s December 11, 2025 press release?

The press release is titled “Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program.” It indicates encouraging permeation kinetics data that support continued development of the company’s intranasal naloxone hydrogel program.

Which exhibit is attached to Polyrizon Ltd.’s December 2025 Form 6-K?

The Form 6-K includes Exhibit 99.1, which is the press release titled “Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program.” This exhibit is incorporated by reference into the report’s contents section.

Who signed Polyrizon Ltd.’s December 11, 2025 Form 6-K filing?

The Form 6-K was signed on behalf of Polyrizon Ltd. by Tomer Izraeli. He is identified in the signature block as the company’s Chief Executive Officer, acting as the duly authorized representative for this report.

Where is Polyrizon Ltd. headquartered according to this Form 6-K?

Polyrizon Ltd. lists its principal executive offices at 5 Ha-Tidhar Street, Raanana, 4366507, Israel. This address identifies the company’s primary location for corporate operations in the Form 6-K header information.